Which funds bought or sold ALNY in Q3 2026?
Alnylam Pharmaceuticals Inc. 9 funds bought, 3 sold, out of 109 tracked funds that have filed for Q3 2026. Among active managers, the estimated net flow was +$2.7B.
Holdings as of Sep 30, 2026 (Q3 2026)13F deadline Nov 16, 2026 (45 days after quarter end)
- T. Rowe Price+$1.1B
- Baillie Gifford+$753M
- Capital World+$660M
- Wellington+$338M
- Capital Research+$294M
- AQR+$240M
- Bank of America+$182M
- Brown Advisory+$172M
- Dodge & Cox+$13M
- Fidelity−$593M
- Two Sigma−$254M
- QRT−$167M
Top 10 each side. NEW = opened a position, OUT = sold the whole position.
Bought (9)
| Fund | Change | Est. $ | Now |
|---|---|---|---|
| T. Rowe Price Asset manager | Added+77.4% | +$1.1B | $2.5B |
| Baillie Gifford Growth / crossover | Added+125.1% | +$753M | $1.4B |
| Capital World Asset manager | Added+24% | +$660M | $3.4B |
| Wellington Asset manager | Added+64.8% | +$338M | $858M |
| Capital Research Asset manager | Added+12.2% | +$294M | $2.7B |
| AQR Quant & multi-strategy | Added+133.5% | +$240M | $419M |
| Bank of America Bank & broker | Added+74.2% | +$182M | $427M |
| Brown Advisory Asset manager | Added+901% | +$172M | $191M |
| Dodge & Cox Value investor | Added+2.6% | +$13M | $495M |
Sold (3)
Source: SEC EDGAR Form 13F-HR for each fund, holdings as of Sep 30, 2026. Shares only (options excluded). Estimated $ = change in shares × quarter-end price. Funds may have traded since. Methodology. Not investment advice.